Temple: When Zomato founder and Eternal CEO Deepinder Goyal appeared on Raj Shamani’s Figuring Out podcast, the conversation quickly shifted online from business to a small metallic device clipped near his temple. Within hours, social media was packed with guesses, memes and searches trying to identify the gadget.
The device is called Temple, an experimental wearable that its developers say is designed to track cerebral blood flow continuously and in real time. Goyal has described it publicly as a research prototype and not a consumer product, and the device is not part of Zomato’s business.
Also Read | India’s first government AI clinic opens at GIMS Greater Noida
According to reports, Temple is linked to a separate health-tech effort connected with Goyal’s privately funded longevity initiative, Continue Research. Goyal has said he has been testing the sensor on himself for an extended period as part of broader personal experiments around health optimisation, which have included tracking biomarkers and lifestyle routines.
Goyal has also discussed what he calls the “Gravity Ageing Hypothesis,” suggesting that gravity may contribute over decades to reduced blood flow to the brain by chronically challenging circulation. He has framed the idea as a hypothesis rather than settled science, positioning Temple as a tool to collect continuous data that could help evaluate whether long-term shifts in cerebral blood flow are linked to ageing-related decline.
Temple is not currently available for sale, and there is no announced price or launch timeline, according to multiple reports. Some coverage has described the company as exploring an early-access or limited research rollout before any broader availability.
On the funding side, Outlook Business reported in December 2025 that the wearable start-up was in talks to raise a $50 million seed round, with interest from investors including Steadview Capital, Vy Capital and others. The same report said Goyal had already put significant capital into Continue Research.
Medical experts, however, have urged caution about drawing clinical conclusions from a temple-mounted sensor. In an NDTV report, neurosurgeon Vishwanathan Iyer said a device placed on the temple may capture surface-level signals and should not be confused with direct measurements of cerebral blood flow from hospital-based imaging such as MRI.
Other commentary has questioned the scientific standing of the product’s claims at this stage. A Times of India report cited an AIIMS doctor criticising the device’s clinical validity and warning that evidence and rigorous testing are essential before such wearables can be treated as medically meaningful tools.
For now, Temple remains a high-profile research prototype, one that has sparked widespread curiosity online, but also renewed debate over how quickly wellness wearables can move from experimental data collection to clinically validated health technology.
